Researchers receive multi-million-dollar grant to expand kidney research

NewsGuard 100/100 Score

Researchers at University of California San Diego School of Medicine and the University of Alabama at Birmingham School of Medicine (UAB) have received renewed grant funding from the National Institute of Diabetes and Digestive and Kidney Diseases to expand research into the areas of acute kidney failure and acute kidney injuries.

The 5-year, $5.67 million will fund the O'Brien Center for Acute Kidney Injury Research at UAB and UC San Diego School of Medicine. The center is one of eight federally funded locations using state-of-the art technologies and resources to train researchers in kidney diseases.

"We focus on understanding the relationship of acute kidney injury to development of chronic kidney disease and developing novel strategies to map the continuum of the disease for targeted interventions," said Ravindra L. Mehta, MD, nephrologist and professor of medicine at UC San Diego School of Medicine. "The center offers several biomarker assays to evaluate kidney injury and function to improve diagnosis, identify targets for intervention and help decision-making for physicians managing patients with these diseases."

Mehta and colleagues contribute significantly to all three core components of the center. The clinical component is led by Mehta and develops infrastructure and resources that translate basic research findings to clinical applications. The preclinical core is headed by UAB, but co-directed at UC San Diego School of Medicine by Volker Vallon, MD, professor of medicine and pharmacology. It develops experimental models of acute kidney injury to understand underlying mechanisms and pathophysiology, and provides training workshops for investigators. Additionally, UC San Diego School of Medicine is home to a biomarker laboratory that supports and provides new research methodologies, biomarker assays and training through workshops and consultations.

"This new grant will allow both UC San Diego School of Medicine and UAB to be continued collaborators and leaders in this field," said Joachim H. Ix, MD, chief of the Division of Nephrology-Hypertension, at UC San Diego School of Medicine. "The next five years will only build upon the great work that has been ongoing since 2008."

"Acute kidney injury causes more deaths per year than breast cancer, prostate cancer, heart failure and diabetes combined," said Anupam Agarwal, MD, director of the Division of Nephrology at UAB and director of the O'Brien Center collaboration. "The center helps with our mission to improve the health of patients by fostering research that is centered on the prevention and treatment of acute kidney injury and its complications."

Acute kidney failure and acute kidney injury affect approximately 1.2 million hospitalized patients per year. Both acute kidney failure and kidney injury are common in patients who are already hospitalized. Symptoms include decreased urine output, nausea and fatigue. In some cases, however, symptoms are minimal.

The network of O'Brien Centers were established in 1987 and named for George M. O'Brien, a member of the U.S. House of Representatives. All O'Brien Centers conduct interdisciplinary investigations that address basic, clinical and applied aspects of biomedical research in kidney physiology and pathophysiology. Most investigations emphasize kidney diseases of hypertension and diabetes, immune- and nonimmune-related mechanisms of kidney disease, nephrotoxins and cell injury.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 3 trial shows overall survival benefit from adjuvant therapy in kidney cancer patients